Precision BioSciences to Present at Upcoming Investor Conferences
26. Mai 2020 16:01 ET
|
Precision Biosciences
DURHAM, N.C., May 26, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...
Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update
15. Mai 2020 07:00 ET
|
Precision Biosciences
Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL PBCAR0191 Phase 1/2a Trial is Progressing with Updated Interim Data Expected in 2020; Phase 1/2a...
Precision BioSciences to Report First Quarter 2020 Financial Results and Present at Bank of America Securities Health Care Conference 2020
07. Mai 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary...
Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
28. April 2020 16:45 ET
|
Precision Biosciences
DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,...
Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources
15. April 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., April 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,...
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL
07. April 2020 07:00 ET
|
Precision Biosciences
PBCAR20A targets CD20 and is the Company’s second investigational allogeneic CAR T candidate advanced to the clinic FDA has authorized Precision to begin dosing with PBCAR20A at Dose Level 2 DURHAM,...
Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano
11. März 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering,...
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
10. März 2020 07:05 ET
|
Precision Biosciences
-Presented initial clinical data for lead allogeneic CAR T program PBCAR0191 for the treatment of NHL and B-ALL- -Implemented amendment to PBCAR0191 Phase 1/2a trial focused on optimizing clinical...
Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences
21. Februar 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary...
Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma
13. Januar 2020 07:00 ET
|
Precision Biosciences
-Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020- -PBCAR269A...